Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) insider James Patrick Tursi sold 9,960 shares of Aralez Pharmaceuticals stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $2.50, for a total transaction of $24,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded up 8.30% during midday trading on Wednesday, hitting $2.48. 1,289,248 shares of the stock were exchanged. The stock’s market cap is $165.78 million. Aralez Pharmaceuticals Inc. has a 12 month low of $0.95 and a 12 month high of $5.49. The firm has a 50 day moving average of $1.48 and a 200-day moving average of $1.48.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.01). The company had revenue of $27.62 million during the quarter, compared to the consensus estimate of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 122.35%. The company’s revenue for the quarter was up 119.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.27) earnings per share. Equities research analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.62) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/james-patrick-tursi-sells-9960-shares-of-aralez-pharmaceuticals-inc-arlz-stock.html.

Separately, Chardan Capital cut their target price on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, August 10th.

Several hedge funds and other institutional investors have recently bought and sold shares of ARLZ. Franklin Street Advisors Inc. NC grew its holdings in shares of Aralez Pharmaceuticals by 67.5% in the second quarter. Franklin Street Advisors Inc. NC now owns 99,229 shares of the company’s stock worth $134,000 after purchasing an additional 40,000 shares during the last quarter. Salzhauer Michael grew its holdings in shares of Aralez Pharmaceuticals by 4.5% in the second quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock worth $144,000 after purchasing an additional 4,600 shares during the last quarter. FNY Managed Accounts LLC grew its holdings in shares of Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock worth $165,000 after purchasing an additional 3,136 shares during the last quarter. Isthmus Partners LLC grew its holdings in shares of Aralez Pharmaceuticals by 0.8% in the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock worth $208,000 after purchasing an additional 1,285 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock worth $260,000 after purchasing an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 23.79% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.